Evaluation of Protective Efficacy of the Synthetic Peptide Vaccine Containing the T-Helper 1 Epitope with Cpg Oligodeoxynucleotide against Feline Infectious Peritonitis Virus Infection in Cats
Free accessResearch articleFirst published online October, 2014
Evaluation of Protective Efficacy of the Synthetic Peptide Vaccine Containing the T-Helper 1 Epitope with Cpg Oligodeoxynucleotide against Feline Infectious Peritonitis Virus Infection in Cats
Feline infectious peritonitis (FIP) is a feline coronavirus-induced fatal disease in domestic and wild cats. Cellular immunity is considered to play an important role in the prevention of FIP. Thus, induction of the cellular immune response is essential in vaccines against FIP virus (FIPV) infection.
Methods
We immunized cats with peptides containing T-helper (Th)1 epitopes derived from the nucleocapsid (N) protein of the type I FIPV KU-2 strain (NP7 and NP8) with feline CpG-oligodeoxynucleotides (fCpG-ODNs) as a vaccine adjuvant.
Results
Prevention against type II FIPV 79-1146 strain-induced FIP was slightly better in specific pathogen-free cats treated with NP7 and NP8 with fCpG-ODNs. However, immune tolerance was suggested to be induced by the high dose and frequency of NP7 and NP8 with fCpG-ODNs.
Conclusions
Further investigations on the combination and concentrations of the peptides and fCpG-ODNs, dose, frequency and route of administration are needed.
References
1.
KsiazekT.G., ErdmanD., GoldsmithC.S.A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med2003; 348: 1953–1966.
2.
ReuskenC.B., HaagmansB.L., MüllerM.A.Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis2013; 13: 859–866.
3.
PedersenN.C.A review of feline infectious peritonitis virus infection: 1963–2008. J Feline Med Surg2009; 11: 225–258.
4.
PetersenN.C., BoyleJ.F.Immunologic phenomena in the effusive form of feline infectious peritonitis. Am J Vet Res1980; 41: 868–876.
5.
WeissR.C., ScottF.W.Antibody-dependent enhancement of disease in feline infectious peritonitis virus: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis1981; 4: 175–189.
6.
KissI., PolandA.M., PedersenN.C.Disease outcome and cytokine responses in cats immunized with an avirulent feline infectious peritonitis virus (FIPV)-UCD1 and challenge-exposed with virulent FIPV-UCD-8. J Feline Med Surg2004; 6: 89–97.
7.
WeissR.C., CoxN.R.Delayed-type hypersensitivity skin response associated with feline infectious peritonitis in two cats. Res Vet Sci1988; 44: 396–398.
8.
HohdatsuT., YamatoH., OhkawaT.Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP. Vet Microbiol2003; 97: 31–44.
9.
LiuJ., SunY., QiJ.The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis2010; 202: 1171–1180.
10.
SatohR., FurukawaT., KotakeM.Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid protein of feline infectious peritonitis virus. Vaccine2011; 29: 1791–1800.
11.
SatohR., KotakeM., TakanoT.Identification of cytosine-phosphorothioate-guanine oligodeoxynucleotide sequences that induce interferon-γ production in feline immune cells. Microbiol Immunol2011; 55: 184–190.
12.
SatohR., KakuA., SatomuraM.Development of monoclonal antibodies (MAbs) to feline interferon (fIFN)-γ as tools to evaluate cellular immune responses to feline infectious peritonitis virus (FIPV). J Feline Med Surg2011; 13: 427–435.
13.
AicheleP., Brduscha-RiemK., OehenS.Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity1997; 6: 519–529.
14.
MiconnetI., KoenigS., SpeiserD.CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol2002; 168: 1212–1218.
15.
SpeiserD.E., LiénardD., RuferN.Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest2005; 115: 739–746.
16.
ChenM., SällbergM., HughesJ.Immune tolerance split between hepatitis B virus precore and core proteins. J Virol2005; 79: 3016–3027.
17.
GarzaK.M., ChanS.M., SuriR.Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med2000; 191: 2021–2027.
GearyS.M., LemkeC.D., LubaroffD.M.Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunol Immunother2011; 60: 1309–1317.
20.
VermeulenB.L., DevriendtB., OlyslaegersD.A.Suppression of NK cells and regulatory T lymphocytes in cats naturally infected with feline infectious peritonitis virus. Vet Microbiol2013; 164: 46–59.
